Latest News

  • New clinical research measures needed to ensure patient safety and advance drug development
    New campaign launches on inaugural World Patient Safety Day Maidenhead, United Kingdom, 17 September 2019 – IAOCR has launched a new campaign calling on the industry to prioritize ensuring the competence of those undertaking clinical research in-line with upcoming guideline changes. The ‘Don’t Risk Your Research’ campaign, launched on World Patient Safety Day, further supports the imminent changes to ICH E8(R1) which focuses on factors improving the ‘quality’ of clinical research specifically around the “Right First Time” approach to quality assurance.
  • This week in Drug Discovery Today
    As a service from Drug Discovery Today, we are beginning to highlight those papers that have been published as "Articles in Press" either as corrected or uncorrected proofs in the preceding week. We hope that they are of interest to you. The articles are citable via their doi.
  • Elypta and Patrik Hollos of Åbo Akademi University Win Nordic Life Science Award 2019
    Ten life science companies, two from each Nordic country, were nominated for the Nordic Life Science Award 2019. Winners of the Academic Class and Business Class, both jury-evaluated, and Delegates’ Choice, or audience-evaluated, have finally been announced during Nordic Life Science Days (NLSDays).
  • Virus lasers open up new avenues for monitoring biology
    Virus lasers have the potential to become a once-in-a-generation analytical technology that will have a transformative impact in biological manufacturing, clinical diagnostics, and environmental sensing.
  • Lab Innovations 2019 to showcase advances shaping the laboratories of the future
    Game-changing instrumentation and presentations spanning new regulations to artificial intelligence feature in the UK’s most forward-thinking laboratory event
view more


view more


  • The Promise of Epigenetics in Early Stage Drug Discovery
    Epigenetic targets are exciting to drug discovery scientists because they hold great potential across a wide spectrum of therapeutic areas. The field of epigenetics focuses on the investigation of enzymes that alter gene expression through modification of their target substrates, usually through the addition or removal of methyl or acetyl groups. High-throughput assays to identify agents capable of modifying the action of such enzyme targets has, in the past, proven to be challenging due to the relatively small molecular alterations in addition to the possibility of sequential modifications, leading to multiple end products. As such, high-throughput bioassays that allow the direct, concurrent quantification of multiple modification states are attractive. The RapidFire platform enables high-throughput mass spectrometric analysis of native molecules from in vitro reactions by performing on-line desalting in seconds, as opposed to HPLC, which requires minutes. Moreover, the RapidFire system can be connected to any mass spectrometer providing unparalleled versatility in reaction detection.
  • Integrated Quant / Qual for In-vivo Discovery Bioanalysis using Hybrid Quadrupole-Time-of-Flight Mass Spectrometry
    Ultra high performance liquid chromatography (UHPLC) coupled with orthogonal acceleration hybrid quadrupole-time-of-flight (QqTOF) mass spectrometry is an emerging technique offering new strategies for the efficient screening of new chemical entities (NCE) and related molecules at the early discovery stage within the pharmaceutical industry.
  • Drug Delivery: enabling technology for discovery and development
    The integration of pharmacodynamic and pharmacokinetic parameters in non clinical pharmacology studies is a key aspect in drug discovery for efficacy and safety assessment, in the particular for the translation from the non clinical to the clinical field. Modeling the profile of plasma exposure achieved with the intended therapeutic route often requires the use of intravenous infusion. In addition, in most cases infusion parameters (infusion rate, volume, duration and sequences) need to be customized to achieve the appropriate pattern of plasma drug exposure. When pharmacodynamic parameters are recorded by telemetry, the use of implantable pumps rather than external pumps is necessary to preserve the improvement in physiological data recording offered by telemetry.
  • Part 2: How has HR-MS technology fundamentally changed the way we study drug biotransformation and disposition?
    AB SCIEX is proud to present the 2nd installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 2 of this webinar series will focus on how HRMS technology has fundamentally changed the way metabolite biotransformations are investigated in Lead Discovery.
view more


view more


  • Bicyclic peptides: types, synthesis and applications
    Bicyclic peptides categorized into two groups: natural and synthetic. • Bicyclic peptides form one of the promising platforms for drug development owing to their biocompatibility, similarity and chemical diversity to proteins. • Bicyclic peptides can be employed as effective alternatives to complex molecules, such as antibodies, or small chemical molecules. Bicyclic peptides can be used as antimicrobial agents, drug targeting, imaging and diagnosis agents and therapeutics tools.
  • Host-defense peptides and their potential use as biomarkers in human diseases
    • Host-defence peptides (HDPs) play a crucial role in innate and adaptive immunity. • Mutations in HDPs are worldwide spread and are population-specific. • HDPs may be correlated to various diseases making potential biomarker.
  • Peptide-based therapeutics: quality specifications, regulatory considerations, and prospects
    • Harmonized pharmacopoeial peptide monograph will reduce manufacturer’s burden. • Quality assessment of peptides is crucial to ensure optimal safety to patients. • Purity characterization of peptides is critical for development of peptide therapeutics. • Global peptides therapeutic market is predicted to flourish in near future.
  • Solid nanoparticles for oral delivery of antimicrobials: A review
    Solid nanoparticles can be used as carriers for antimicrobial drugs. • Provide better solutions for challenges related to oral antimicrobial drug delivery. • Improve the efficacy of antimicrobials to achieve the desired effect.
  • Design strategies for chemical stimuli-responsive programmable nanotherapeutics
    Various chemical stimuli existing in the biological systems are discussed. • Strategies for designing chemical stimuli-responsive nanocarriers are summarized. • Biomedical applications of chemical stimuli-responsive nanocarriers are reviewed. • Limitations and future perspectives of current nanotherapeutics are addressed.
view more

25 Hottest Articles

view more